Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT06224049RecruitingEarly Phase 1
New immune cells for Epstein-Barr virus positive T-cell lymphoma
This trial tests a new treatment using specially designed immune cells (called hNeo-T cells) to attack Epstein-Barr virus positive T-cell lymphoma that has come back or not responded to standard therapy. The treatment is personalized based on your tumor's unique markers and your tissue type (HLA).
Shenzhen, GuangdongAges 18–75 - NCT06224634Recruiting
Testing a new drug for airway problems
This trial tests how a drug called anti-IL-17 affects your airways. If you are already planning to take this drug, researchers want to see if it helps with breathing and airway resistance.
Hvidovre, Capital RegionAges 18 years+ - NCT06225310RecruitingPhase 1
New combo for relapsed/refractory multiple myeloma
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
West Hollywood, CaliforniaAges Any age - NCT06226155Recruiting
HIV prevention support for pregnant women in Zimbabwe
This study in Zimbabwe tests a program to help pregnant women start and stay on PrEP (medication that prevents HIV). It aims to make PrEP easier to use during pregnancy for women who are at risk of HIV.
HarareAges 15–55 - NCT06228794Recruiting
CPC blood test to predict multiple myeloma outcomes
This trial is studying a new blood test that measures circulating plasma cells (CPCs) to help predict how multiple myeloma may progress. It is for people newly diagnosed with multiple myeloma who have not yet started treatment.
Wuhan, HubeiAges 18–80 - NCT06230458Recruiting
FeNO breath test to help diagnose asthma
This trial is testing whether a simple breath test called FeNO can help doctors diagnose asthma more accurately. It's for people who have symptoms that might be asthma, but haven't been diagnosed yet.
Rotterdam, South HollandAges 18 years+ - NCT06232096RecruitingPhase 1/Phase 2
Study of MBS314 for relapsed or refractory multiple myeloma
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
BeijingAges 18 years+ - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06234384Recruiting
Sarcoidosis advanced registry study
This study is creating a registry of people with sarcoidosis to help researchers better understand the disease and develop new treatments.
Chicago, IllinoisAges 7 years+ - NCT06235229RecruitingPhase 1/Phase 2
GC012F for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
BeijingAges 18–75 - NCT06235580Recruiting
Genetics and immune-brain health study
This study looks at genetic diseases that affect the immune system and the brain. It aims to better understand these conditions by comparing patients, their relatives, and healthy controls.
Paris, Île-de-France RegionAges Any age - NCT06235645Recruiting
Detecting lung disease in rheumatoid arthritis with ultrasound
This study tests if a lung ultrasound can detect early signs of lung disease in people with rheumatoid arthritis. It may help you if you have certain risk factors, like being male, older, or a smoker.
ToursAges 18 years+ - NCT06236373Recruiting
Understanding cancer survivors' needs in Reggio Emilia
This study aims to understand the challenges and needs of people who have survived certain cancers (breast, prostate, thyroid, colorectal, multiple myeloma, or lymphoma) and their caregivers. It uses interviews or focus groups to gather perspectives.
Reggio Emilia, Reggio EmiliaAges 18 years+ - NCT06236607Recruiting
Artificial pancreas trial for adults with type 1 diabetes
This trial tests a hybrid closed-loop system that automatically adjusts insulin delivery. It may help you manage your blood sugar more easily if you currently give yourself daily insulin shots.
Boston, MassachusettsAges 18–75 - NCT06237192Recruiting
Treatment for adults with Ph-negative ALL
This trial tests a less intensive but continuous treatment approach for adults newly diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to improve outcomes by using minimal residual disease (MRD) to guide therapy.
MoscowAges 18–55 - NCT06237660Recruiting
Wheeze study for young children
This study looks at young children (ages 1-5) who have had severe wheezing episodes that needed hospital care. It aims to find biomarkers (clues in the body) that could help predict which children might develop asthma later.
LondonAges 1–5 - NCT06237803Recruiting
Blood sample collection for plasma cell disorders
This study is collecting blood samples from people with plasma cell disorders to help researchers learn more about these conditions. It may be a good fit if you haven't started treatment yet and are willing to donate samples.
MelbourneAges 18 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT06240299Recruiting
Neurofeedback for chronic pain in rheumatoid arthritis
This trial tests a brain-training technique called neurofeedback to see if it can help people with rheumatoid arthritis who also have chronic widespread pain. It uses a computer to show you your brain activity and teach you to control it, which may reduce pain.
Glasgow, ScotlandAges 18–75 - NCT06241482Recruiting
Enhanced recovery after brain surgery in intensive care
This study tests a special recovery program for people with serious brain injuries or strokes who need intensive care. The program focuses on helping you heal faster after surgery.
ShanghaiAges 18–75 - NCT06241521Recruiting
Myasthenia gravis patient registry in China
This study creates a registry to collect information about people with myasthenia gravis in China. By joining, you help researchers learn more about the condition and how it affects different people.
Beijing, Beijing MunicipalityAges Any age - NCT06241729Recruiting
Observation of first-time DLBCL treatment at Charleroi hospital
This study is watching how people with newly diagnosed diffuse large B cell lymphoma (a blood cancer) are treated for the first time at Grand Hôpital de Charleroi. It collects information to help doctors learn more about the disease and its care.
Charleroi, HainautAges 18 years+ - NCT06242327Recruiting
Study of outcomes in primary membranous nephropathy
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
Bergamo, BGAges 18 years+ - NCT06244264Recruiting
Using your own blood during spine surgery for lung cancer
This study tests the safety and effectiveness of using your own blood (collected before surgery) during spine surgery for lung cancer that has spread to the backbone. It may help people whose spine is unstable or causing nerve problems.
Guangzhou, GuangdongAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.